Cerebral Malaria as a Complication of Plasmodium Vivax

Dr. Shashank Shekhar\textsuperscript{1}, Dr. Dipti Neha\textsuperscript{2}, Dr. Amar Verma\textsuperscript{3}
\textsuperscript{1}Junior Resident, \textsuperscript{2}Senior Resident, \textsuperscript{3}Associate Professor

Department of Pediatrics and Neonatology, Rajendra Institute of Medical Sciences (RIMS), Ranchi, Jharkhand

Abstract

**Background:** Cerebral malaria is a diffuse encephalopathy characterised by unarousable coma of more than 30 minutes duration associated with or without seizures. Usually cerebral malaria is caused by P. falciparum, but rarely it could be the presenting complication or occurring during the course of P. vivax. P. vivax is responsible for benign, uncomplicated disease. Newer reports are now suggestive of severe manifestations of P. vivax malaria.

**Objective:** To assess the natural history, associated complications, response to treatment and outcome of cerebral malaria due to P. vivax.

**Methodology:** This study is a hospital based prospective study conducted from September 2015 to August 2016 in Department of Paediatrics and Neonatology, Rajendra Institute of Medical Sciences, Ranchi. In this study, 110 confirmed cases of severe complicated malaria diagnosed on the basis of blood smear examination were included.

**Results:** Out of 110 cases of severe complicated malaria admitted during this period, 35 patients (31.8\%) presented with cerebral malaria of which 23 were due to P. falciparum, 8 due to P. vivax and rest 8 were due to mixed infections. The predominant clinical manifestations were fever, seizures and altered sensorium. Main associated complications were severe anaemia (62\%) and thrombocytopenia (50\%). All the patients responded to IV artesunate. Follow-up evaluation after one month showed no residual neurological deficit.

**Conclusion:** P. vivax infection is usually presumed to cause only uncomplicated malaria but in the last few years, there have been many reports regarding cerebral vivax malaria, the exact pathological mechanism is still elusive. Patients of vivax malaria should be monitored for occurrence of different complications as their early detection and treatment can be life saving.

**Keywords:** P. vivax, cerebral malaria

I. Introduction

Malaria is one of the most important parasitic diseases of humans. Approximately 40\% of the world’s population lives in regions where malaria transmission is endemic. The World Health Organization (WHO) estimated that 214 million cases of malaria occurred globally and approximately 438,000 deaths were recorded in 2015.\textsuperscript{1} Of the various Plasmodium species affecting humans, Plasmodium vivax malaria is long considered to have a benign course. It is known for multiple relapses; but the typical complications seen with falciparum malaria are not found with vivax monoinfection.\textsuperscript{2} However in the past few years there is a changing trend in the clinical manifestations of vivax malaria namely severe complicated disease. Cerebral malaria is a diffuse encephalopathy characterised by unarousable coma of more than 30 minutes duration associated with or without seizures. Usually cerebral malaria is caused by P. falciparum, but rarely it could be the presenting complication or occurring during the course of P. vivax. Only 45 cases of cerebral malaria due to P. vivax are reported in the scientific literature since 1920.\textsuperscript{3}

II. Methodology

This study is a hospital based prospective study conducted from September 2015 to August 2016 in the Department of Paediatrics and Neonatology, Rajendra Institute of Medical Sciences, Ranchi. In this study, 110 confirmed cases of severe complicated malaria diagnosed on the basis of blood smear examination were included. Investigations included complete blood count with peripheral blood smear, random blood sugar, serum electrolytes, renal function test and liver function test.

III. Results

Out of 110 cases of severe complicated malaria admitted during this period, 35 patients presented with cerebral malaria of which 23 (54\%) were due to P. falciparum, 8 (23\%) due to P. vivax and rest 8 (23\%) were due to mixed infections. (Fig 1)
Out of 8 cases of cerebral malaria due to P.vivax, majority of the cases i.e. 4 cases (50%) presented on day 5, 2 cases (25%) on day 3, 1 case (12.5%) each on day 4 and day 7. (Fig 2)

The predominant clinical manifestations were fever, seizures and altered sensorium which were present in all the 8 cases (100%). Other clinical manifestations were headache which was present in 6 cases (75%), vomiting in 3 cases (37.5%). (Fig 3)
Complications seen in these patients were: 5 (62.5%) had severe anaemia, 4 (50%) had thrombocytopenia, 2 (25%) had jaundice, 2 (25%) patients had hypernatremia and 1 (12.5%) presented with DIC. (Fig 4)

![Complications](image1)

**Fig 4:** Case distribution according to complications

All the patients were treated with intravenous artesunate and supportive therapy as required. Repeat blood smears were done for parasitic clearance. Out of 8 cases, 4 (50%) cases attained parasitic clearance on Day 3, 2 (25%) on Day 5 and 1 (12.5%) each on Day 4 and Day 7. (Fig 5)

![Day of parasitic clearance](image2)

**Fig 5:** Case distribution according to day of parasitic clearance

All the eight patients were discharged from the hospital in a clinically stable condition and were advised to take primaquine for 14 days. Two of the eight patients had neurological deficits in form of hemiparesis and one of them had aphasia at the time of discharge. Follow-up evaluation after one month showed no residual neurological deficit.

**IV. Discussion**

Plasmodium falciparum is considered to be the main cause of severe complicated malaria but Plasmodium vivax is being increasingly recognised as one of the etiological factors for severe complicated malaria. Out of 35 cases of cerebral malaria, 8 cases (23%) were due to P. vivax monoinfection. The predominant clinical manifestations were fever, seizures and altered sensorium with mean day of presentation being 4.62 ± 1.30 days. The most common complications seen were severe anaemia (62%) and thrombocytopenia (50%). All the patients responded to IV artesunate with mean day of parasitic clearance being around 4.12 ± 1.45 days. There was no residual neurological deficit at 1 month of follow up. Organ dysfunction characteristic of P. falciparum infection is unusual in P. vivax illness. P. vivax malaria earlier thought to be benign isn’t quite benign any more.
Cerebral Malaria As A Complication Of Plasmodium Vivax

Any patient infected with P. vivax who exhibits severe malaria is presumed to be suffering from mixed infection. However, that may not be always true. As evident from the present study, P. vivax infection can also present as cerebral malaria. Clinical data provided by Kochar et al\(^\text{10}\), indicates that P. vivax can cause both sequestration related and non sequestration related complications of severe malaria, all of which are commonly associated with P. falciparum infections. The exact pathogenesis however remains elusive.

V. Conclusion

P. vivax infection is responsible for 60 - 70% of malaria cases in India and it is the most important cause of morbidity. It is usually presumed to cause only uncomplicated malaria but in the last few years, there have been many reports regarding cerebral vivax malaria, the exact pathological mechanism is still elusive. Patients of vivax malaria should be monitored for occurrence of different complications as their early detection and treatment can be life saving.

References


<table>
<thead>
<tr>
<th>Studies</th>
<th>Age Group</th>
<th>No. of Severe Complicated Malaria Cases</th>
<th>No. Of Cerebral Malaria Cases Due To P. Vivax</th>
</tr>
</thead>
<tbody>
<tr>
<td>Charulata S Limaye Et Al, 2012</td>
<td>Adults</td>
<td>162</td>
<td>12 (7.4%)</td>
</tr>
<tr>
<td>Rajesh Kumar Et Al, 2014</td>
<td>0-15 Years</td>
<td>81</td>
<td>5 (6.1%)</td>
</tr>
<tr>
<td>Suman Sarkar Et Al, 2008</td>
<td>Adults</td>
<td>-</td>
<td>3</td>
</tr>
<tr>
<td>Shoba Philip Et Al, 2015</td>
<td>Adults</td>
<td>-</td>
<td>1</td>
</tr>
<tr>
<td>Ravi Bhatia Et Al, 2014</td>
<td>9 Years</td>
<td>-</td>
<td>1</td>
</tr>
<tr>
<td>Singh Et Al, 2014</td>
<td>Adults</td>
<td>110</td>
<td>19 (17.2%)</td>
</tr>
<tr>
<td>Present Study</td>
<td>1-15 Years</td>
<td>110</td>
<td>8 (7.3%)</td>
</tr>
</tbody>
</table>

Fig 6: Cerebral Malaria cases due to P. vivax in different studies